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Abstract
Mitochondrial impairment, glutathione depletion and oxidative stress have been 
implicated in the pathogenesis of Parkinson’s disease, linked recently to proteasomal 
dysfunction. Our study analysed how these factors influence the various activities of 
the proteasome in human SH-SY5Y neuroblastoma cells treated with the PD mimetics 
MPP+ (a complex 1 inhibitor) or dopamine. Treatment with these toxins led to dose 
and time dependent reductions in ATP and glutathione and also chymotrypsin-like 
and post-acidic like activities; trypsin-like activity was unaffected.
Anti-oxidants blocked the effects of dopamine, but not MPP+, suggesting that 
oxidative stress was more important in the dopamine-mediated effects. With MPP+, 
ATP depletion was a pre-requisite for loss of proteasomal activity. Thus in a 
dopaminergic neuron with complex 1 dysfunction both oxidative stress and ATP 
depletion will contribute independently to loss of proteasomal function.
We show for the first time that addition of MPP+ or dopamine to purified samples of 
the human 20S proteasome also reduced proteasomal activities; with dopamine being 
most damaging. As with toxin- treated cells, chymotrypsin-like activity was most 
sensitive and trypsin-like activity the least sensitiv . The observed differential 
sensitivity of the various proteasomal activities to PD mimetics is novel and its 
significance needs further study in human cells.
Running Title: Parkinson’s Disease Mimetics on proteasomeal activity.
Keywords: 20S proteasome, MPP+, dopamine, SH-SY5Y, Parkinson’s 
disease, dysfunction.
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Introduction
Parkinson’s Disease (PD) is one of the most common age-related neurodegenerative 
disease affecting around 1 % of the population aged over 65 years. The pathological 
hallmark is selective degeneration of the dopamine-containing neurons of the substantia 
nigra pars compacta, accompanied by the intracytoplasmic accumulation of Lewy body
inclusions containing aggregated, nitrated, oxidised and ubiquitinated proteins (Forno, 
1996; Good et al. 1998; Kowall et al. 2000; Lopiano et al. 2000; McNaught and Olanow 
2006). The proteins present include -synuclein, neurofilaments, ubiquitin, and 
proteasomal subunits. 
In sporadic cases of PD, nigral pathology is associated with mitochondrial dysfunction, 
notably a reduced activity of complex 1 of the electron transport chain (Schapira et al.
1990; McNaught et al. 2001; Orth and Schapira 2002). Indeed, agents which inhibit 
complex 1, such as 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone, 
produce selective degeneration of dopaminergic neurons in animal models (Beal 2001). 
MPTP is oxidised by monoamine oxidase to the potent neurotoxin 1-methyl-4-
phenylpyridinium (MPP+), which selectively accumulates in dopaminergic neurons via 
the dopamine uptake transporter and is occasionally associated with the formation of 
intraneuronal inclusions reminiscent of Lewy bodies (Kowall et al. 2000). Although the 
specificity of rotenone has been questioned (Perier et al. 2003), chronic rotenone 
treatments, both in vivo and in vitro, have been reported to lead to the formation of 
insoluble aggregates of synuclein (Betarbet et al. 2000; Sherer et al. 2002). Although 
rotenone does not concentrate in dopaminergic neurons, it induces selective dopamine
cell death, suggesting that these neurons are uniquely sensitive to complex 1 
impairments; this may be linked to dopamine itself (see below).
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Oxidative stress, accompanied by depletion of the antioxidant glutathione, is also 
thought to contribute to the disease (Gu et al. 1998; Riederer et al. 1989). Reactive
oxygen species (ROS) may be produced during oxidative phosphorylation; within 
complex 1, upstream of the MPP+/rotenone binding site, which is a site of electron 
leakage that enhances ROS formation (Hensley et al. 1998). In addition, dopamine 
metabolism is another source of ROS (Cassarino et al. 1998) and dopamine is implicated 
in the etiology of PD irrespective of its role as a neurotransmitter. Selective degeneration 
of dopaminergic neurons with MPTP/MPP+ is reported to trigger a rapid efflux of 
dopamine from intracellular vesicles (Santiago et al., 1995), exacerbating oxidative 
stress. Normal catabolism of dopamine via the flavoprotein monoamine oxidase 
produces hydrogen peroxide (Maker et al. 1981). In addition, dopamine can autooxidise 
(Graham et al. 1978) and form reactive quinone and semi-quinone species that are
capable of modifying cellular macromolecules, both by autooxidation and following 
catalysis by various enzymes (such as tyrosinase, cyclooxygenase or peroxidase) and 
metals (such as manganese and iron, Stokes et al. 2000). Under normal conditions
mitochondrial hydrogen peroxide is mainly removed by its enzymatic conversion to 
water by glutathione peroxidase (mitochondria lack catalase). If cytoplasmic dopamine 
levels increase, or if cytoplasmic levels are normally high, glutathione will have a very 
important role in the detoxification process. Indeed, dopamine has been associated with 
inhibition of respiration, possibly relating to the effects of its oxidation products (Gluck
et al. 2002), although earlier work regarding the effects of dopamine on mitochondrial 
respiration was contradictory (Blum et al. 2001; Gluck et al. 2002).
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Recent evidence suggests that failure of the ubiquitin proteasome system (UPS) 
contributes to degeneration of dopaminergic neurons and Lewy body formation in 
sporadic PD (McNaught et al. 2001; McNaught and Jenner 2001). This system plays an 
essential role in the degradation and clearance of short-lived, mutant, misfolded or 
damaged proteins in eukaryotes (Goldberg, 1995). The 26S proteasome is a multi-
catalytic protease which contains a catalytic 20S core, comprised of outer heptameric 
rings of  subunits and two inner heptameric rings of catalytically active  subunits. 
Some of the 20S sub-complex is associated in an ATP dependent manner with a 19S 
regulatory particle, making up the 26S complex, which degrades ubiquitinated proteins 
in an ATP-dependent process. The 19S complex utilizes ATP hydrolysis to control 
access of substrate to the 20S proteasome core. The best characterized proteolytic 
activities of the 20S complex are known as chymotrypsin-like, trypsin-like and post-
acidic like (Ferrell et al. 2000).
Impaired protein clearance in the substantia nigra pars compacta is supported by 
evidence of oxidised protein accumulation (Yoritaka et al. 1996; McNaught et al. 2003) 
and by reduced 20S proteasomal activity in nigral post-mortem samples (McNaught et 
al. 2003). The discovery of some rare familial cases linked to genetic mutations lends 
further support to a failure in the UPS. Thus in autosomal dominant PD mutations in the 
gene coding for -synuclein, one of the major components of Lewy bodies, have been 
reported (Polymeropoulos et al. 1997; McNaught et al. 2003). These mutations have 
been thought to cause the protein to misfold and aggregate, impairing its degradation by 
the UPS and inhibiting proteasomal activity (Bennett et al. 1999), although other 
mechanisms have also been proposed (Tofaris et al. 2001; Tofaris et al. 2003). In 
addition, loss of function mutations in two UPS enzymes, parkin (which has E3 
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ubiquitin ligase activity) and ubiquitin carboxy terminal hydrolase-L1, are associated 
with neurodegeneration in some familial forms of PD (reviewed by Farrer 2006).
The association between mitochondrial dysfunction and the proteasomal system in PD 
has recently been a focus of interest (Hoglinger et al. 2003; Shamoto-Nagai et al. 2003;
Duke et al. 2006). For example, Hoglinger et al (2003) studied the effects of complex 1 
inhibition on the survival of primary rat mesencephalic cultures, and attempted to 
correlate this with proteasomal activity and ATP levels. Although this work has 
provided very useful information there has been little or no effort to distinguish between 
the direct and indirect effects of the neurotoxins on proteasomal activity, and the short
time courses used may have overlooked the chronic effects. The work of Hoglinger et al
(2003) was also complicated by the use of primary, non-human (rat) embryonic cell 
cultures which are, by their nature, a mixed population. In addition, no attempt has been 
made to correlate the changes with alterations in glutathione levels, which are reportedly 
reduced in PD brains (Jenner, 1993) and low l vels of which can disrupt the ubiquitin 
proteasomal pathway (Jha et al., 2002). Thus in this study the direct effects of MPP+, 
MPTP and dopamine on the activity of purified human 20S proteasome are compared 
with the effects of the toxins on 20S proteasomal activities of human cells exposed to 
the neurotoxins. Human neuroblastoma SH-SY5Y cells, chosen for this study, are a 
widely used dopaminergic cell model for PD studies since they contain dopamine
(Xavier-Gimenez et al., 2006), monoamine oxidase-A (Jiang et al., 2006) and a 
dopamine re-uptake system (Jiang et al., 2004), all characteristics of the dopaminergic 
neurons that are selectively lost in PD. The association between ATP, cellular 
glutathione, ROS and proteasomal activity in this model are reported in this manuscript. 
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Materials and Methods.
Materials
The source of materials are listed below: Tissue culture plastic ware, Scientific 
Laboratory Supplies (Nottingham, UK); ATP ViaLight® Plus Cell BioAssay kit, 
Cambrex Bioscience Ltd (Wokingham, UK); Human erythrocyte 20S proteasomes, 
Biomol International LP (Exeter, UK); MPP+, dopamine and L-Buthionine-[S,R]-
sulfoximine (BSO) Sigma Aldrich Chemical Co (Poole, UK). The fluorogenic peptide
substrates succinyl-leucine-leucine-valine-tyrosine-7-amido-4-methylcoumarin (Suc-
LLVY-AMC) and boc-leucine-arginine-arginine-7-amido-4-methylcoumarin (Boc-
LRR-AMC) were purchased from Bachem Ltd (St. Helens, UK). The florogenic peptide 
substrate Z-leucine-leucine-Glutamic acid-7-amido-4-methylcoumarin (Z-LLE-AMC), 
recombinant calpain-2 enzyme (#208718) and Calpain Inhibitor III (MDL 28170) were
purchased from Calbiochem (Nottingham, UK). All other chemicals were purchased 
from Sigma Aldrich Chemical Co. (Poole, UK) unless otherwise stated.
Cell culture
SH-SY5Y human neuroblastoma cells (from the European Collection of Animal and 
Cell Cultures) were maintained as a monolayer in Dulbecco’s modified Eagle’s medium 
(DMEM)/Ham´s F12 (1:1) containing 10 % (v/v) heat inactivated foetal bovine serum, 1 
% (v/v) MEM non-essential amino acids, 2mM L-glutamine, 200 units/ml penicillin, 20 
µg/ml streptomycin (Cambrex Bioscience Ltd, Wokingham, UK) at 37oC in a 
humidified atmosphere of 95 % (v/v) air/ 5 % (v/v) CO2 until 70-90 % confluent. Cells 
were used between passages 16-20.
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Protein estimation
Protein estimation of samples was carried out using the BioRad protein assay (BioRad 
Laboratories Ltd, Hemel Hempstead, UK) in accordance with the manufacturer’s 
instructions using bovine serum albumin as a standard.
Viability studies 
SH-SY5Y cells (10,000 cells per well) were cultured in 96-well culture plates in growth 
medium in the presence or absence of either BSO (2 mM), MPP+ (100 µM, 2 mM) or 
dopamine (100 µM, 2 mM) for 24 h, 48 h and 72 h. Cell viability was assessed at each 
time point using the MTT {3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoulium 
bromide; assay (Cookson et al., 1995). Briefly, 1 hour prior to the end of each 
incubation MTT (0.5 mg/ml, final conc) was added to each well and plates re-incubated 
at 37oC for 1 hour. Medium was carefully aspirated from the wells and the endogenous 
formazan product eluted using 100 µl dimethyl sulphoxide. Plates were gently agitated 
to fully dissolve the formazan product, prior to reading the absorbance at 570 nm. Blank 
values were subtracted from each reading and the absorbance then expressed as a 
percentage of the value for the corresponding control.
Determination of ATP levels
SH-SY5Y cells (10,000 cells/well) were cultured in 96 well plates in growth medium 
in the presence or absence of BSO (2 mM), MPP+ (100 µM, 2 mM) or dopamine (100 
µM, 2 mM) for 24 h, 48 h and 72 h. ATP levels were measured using the ViaLight®
Plus Cell BioAssay kit which utilizes luciferase to catalyse the formation of light from 
ATP and luciferin. The emitted light intensity was measured using a FLUOstar 
Optima luminometer (BMG Labtech, UK). Samples were protein estimated using the
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BioRad assay and results were calculated as ATP levels/µg protein and expressed as
% ATP levels in comparison to control samples.
Proteolytic activities
SH-SY5Y cells were plated out in 6-well plates at a density of 500,000 cells/well. 
Cells were exposed to either BSO, MPP+, MPTP or dopamine for 24 h, 48 h or 72 h. 
After the required exposure period cells were detached using a cell scraper, 
centrifuged and washed with DMEM. Cell pellets were resuspended in 250 µl ice-
cold homogenisation buffer [20 mM Tris/HCl, pH 7.2; 0.1 mM EDTA; 1 mM 2-
mercaptoethanol; 5 mM ATP; 20 % (v/v) glycerol; 0.4 % (v/v) Igepal CA-630]. 
Samples were vigorously vortex mixed and cleared of cell debris by centrifugation, 
prior to assessment of proteasome activity. Suc-LLVY-AMC, Boc-LRR-AMC and Z-
LLE-AMC were used to assess chymotrypsin-like (CLA), trypsin-like (TLA) and post 
acidic-like (PLA) activities, respectively (Kisselev & Goldberg, 2005). The 
fluorogenic peptide assay was performed using 20-30 µg of SH-SY5Y cell lysate, in a 
final volume of 200 µl assay buffer (50 mM HEPES pH 8.0, 5 mM EGTA). 
Fluorescence (360nm excitation; 465 nm emission) was measured every 5 minutes up 
to 2 h, linear rates calculated as FU/s/µg protein and expressed as % change in 
comparison to control samples.
The chymotrypsin-like (CLA), trypsin-like (TLA) and post acidic-like (PLA) activities
of purified human erythrocyte 20S proteasome exposed to 10 µM, 100 µM, 500 µM and 
2 mM MPTP, MPP+ and dopamine were also assessed. The fluorogenic peptide assay 
was performed using 0.05 µg 20S proteasome/well in a final volume of 200 µl Assay 
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Buffer measuring fluorescence every 5 minutes as before. The results were expressed as
% change in comparison to control samples.
Activity of commercial calpain (3.6 µg) was assessed using the method described by 
Sasaki et al, (1984) and the substrate Suc-Leu-Tyr-AMC in a total reaction volume of 
100 µl [60 mM imidazole pH 7.3, 5 mM cysteine, 2.5 µM 2-mercaptoethanol, 5 mM 
CaCl2]. Fluoresecence was measured every minute for 20 minutes and results expressed 
as % change in comparison to control samples.
Analysis of total glutathione (GSH and GSSG) by enzymatic detection.
Total glutathione levels were determined using the DTNB-GSSG reductase-recycling 
assay, based on the method described by Anderson (1985), with minor modifications. 
Cells exposed to 2 mM BSO, 100 µM and 2 mM MPP+, MPTP or dopamine for 24 h, 48
h or 72 h, were harvested by trypsinisation. Following washing the resultant cell pellet 
was resuspended in 200µl ice-cold sulphosalicyclic acid, sonicated for 3 x 5 seconds and 
centrifuged at 10,000 g for 5 minutes at 4˚C. Supernatants were then assayed for total 
glutathione content. Separate cell pellets were resuspended in 50 µl 1 M NaOH and 
protein estimated using the BioRad assay. For total glutathione analysis 140 µl NADPH 
(0.33 mM) and 20 µl DTNB (6 mM) were added to 20 µl aliquots of sample
supernatants, GSH standards (20–4000 pmol GSH), or blanks prior to the addition of 10 
µl of glutathione reductase (0.1 U/ml). Samples were made up to 200 µl with assay 
buffer (143 mM sodium phosphate and 6.3 mM sodium EDTA, pH 7.5) and the 
formation of thionitrobenzoic acid was monitored by measuring absorbance at 412 nm 
over 10 min. Concentrations of total glutathione (pmol/µg protein) were calculated from 
the GSH standard curve and expressed as % total glutathione content compared to 
controls.
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Evaluation of ROS 
SH-SY5Y cells were grown in Lab-Tek (NUNC, Scientific Laboratory Supplies, UK) 
chamber slides prior to treatment with MPP+, dopamine or BSO for 72 hours. Levels
of intracellular reactive oxygen species were measured using 2’,7’-
dichlorofluorescein diacetate (DCHDF) dye. Following treatment, medium was 
removed and replaced with 100 µM DCHDF for 30 min at 37oC to allow its 
conversion to dichlorofluorescein. Cell monolayers were then washed with Hank’s 
balanced salt solution and ROS-activated fluorescence detected (excitation 488 nm, 
emission 515 nm) and photographed with a Leica TCS – NT confocal inverted 
microscope (Leica Microsystems, UK). All images were taken using the same laser 
power, gain and objective.
Statistical analysis
Data are expressed as the mean ± the standard error of the mean (SEM) and statistical 
analysis performed using a two-tailed, homoscedastic, Students t-Test with a 95 % 
confidence limit (p < 0.05) or a 99 % confidence limit (p < 0.01).
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Results
Effects of MPP+ and dopamine on SH-SY5Y cell viability.
Before studying the effect of toxins on proteasomal activity, concentrations of the 
toxins that were highly and mildly cytotoxic to mitotic SH-SY5Y cells over a 72 h 
period were established using an MTT reduction assay. This assay is dependent on 
cell integrity and viability and is, more specifically, a measure of metabolic activity.
Figure 1 shows that MPP+ and dopamine reduced cell viability in a dose dependent 
manner. Cell viability was not reduced until 48 h exposure with 100 µM MPP+ (29 % 
reduction cf. controls) whilst 2 mM MPP+ reduced cell viability by 51 % after 24 h.
Dopamine at 100 µM did not affect cell viability until 72 h, reducing viability by 30
%, whilst a 500 µM dose led to a 64 % decrease in cell viability after 24h, similar to 2 
mM MPP+. Cell death did not always increase dramatically during the time course, 
probably due to compensatory metabolic mechanisms that occur when cells are 
stressed (Cookson et al., 1995). BSO toxicity was also assessed. Although, 2 mM 
BSO led to a 90 % reduction in glutathione levels as early as 24 h (see Fig. 6), cell 
viability was not affected until 96 h exposure where viability was reduced by 
approximately 50 % (data not shown).
In subsequent experiments, 100 µM MPP+ and 100 µM dopamine were selected for 
use in SH-SY5Y cells as a mildly toxic dose (~20-30 % reduction in cell viability 
after 72 h) and 2 mM MPP+ and 500 µM dopamine as a highly toxic dose (~60-70 % 
cell viability reduction cf. controls after 72 h).  
 
Specificity of the different proteasomal substrates and inhibitors.
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Before monitoring the effects of mildly and highly cytotoxic levels of MPP+ and 
dopamine on proteasomal activity in SH-SY5Y cells, we next checked the specificity 
of the different proteasomal substrates and inhibitors in our cells in comparison to 
purified human erythrocyte 20S proteasomes.
The fluorogenic substrates Suc-LLVY-AMC, Boc-LLR-AMC and ZLLE-AMC were 
used to represent CLA, TLA and PLA, respectively. In an attempt to determine the 
specificity of these substrates for proteasome-mediated degradation, the effects of 
irreversible proteasome inhibitors (lactacystin and epoxomicin) and a calpain inhibitor 
(MDL 28170) on proteolytic activity was monitored. These inhibitors were directly 
added to purified 20S proteasome, calpain enzyme, and also control cell extracts, 
prior to assessment of protease activity. A summary of the inhibitory effects of these 
inhibitors is given in Table 1.
Lactacystin (10 µM) completely inhibited the CLA of purified 20S, inhibited TLA by 
72 % and had no effect on PLA. In contrast epoxomicin (10 µM), reported to be a 
more specific proteasome inhibitor (Kisselev and Goldberg, 2005), completely 
inhibited both CLA and TLA of purified 20S and inhibited PLA by 80 %. The 
sensitivity of CLA in cell extracts to lactacystin was similar to its sensitivity in 20S, 
but TLA in cell extracts was insensitive to 10 µM lactacystin, as has been reported 
elsewhere for cell extracts (Kisselev & Goldberg, 2005). In cell extracts the 
sensitivities of CLA and PLA to epoxomicin were similar to 20S, suggesting that the 
substrates used for CLA and PLA were specific to the proteasome. In the case of 
TLA, however, epoxomicin reduced the activity by only 25 % suggesting that other 
proteases are cleaving the TLA substrate. 
Page 13 of 47 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14
The calpain enzyme was completely inhibited by 10 µM MDL 28170. Addition of 
MDL 28170 to purified 20S proteasome resulted in 25% and 58% inhibition of CLA 
and TLA, respectively, and no inhibition of PLA. Lactacystin inhibited the activity of 
the calpain enzyme by around 40 % whilst epoxomicin had no effect. This confirms 
that epoxomicin is a more specific proteasome inhibitor than the more commonly 
used inhibitor, lactacystin. In cell extracts, 10 µM MDL 28170 did not inhibit PLA or
CLA but inhibited TLA to a similar extent to 20S-TLA (~ 68 %). This would suggest 
that the TLA substrate can act as a substrate for calpain. Thus in order to estimate 
TLA in cell extracts the highly specific epoxomicin was used subsequently.
Effect of MPP+ and dopamine on proteasomal CLA, PLA and TLA in SH-SY5Y 
cells
The effects of a 72 h exposure to mildly and highly toxic concentrations of MPP+ and 
dopamine on the three proteasomal activities were initially checked. Control cell 
extracts exhibited all three proteolytic activities with the measured trypsin-like 
activity being the most active (Table 2a); this is consistent with data obtained using 
commercial human 20S proteasome (data not shown). To confirm whether the activity 
measured was proteasome-mediated, extracts were assayed in the presence or absence 
of epoxomicin.
Table 2a shows that mildly toxic concentrations of dopamine and MPP+ (100 µM) had 
no effect on the three proteasomal activities. However, highly toxic concentrations of 
MPP+ (2 mM) reduced CLA and PLA by 80-90%. Highly toxic concentrations of 
dopamine (500 µM) had a smaller effect, reducing CLA and PLA by approximately 
50 %, whilst neither toxin reduced TLA. Due to the less specific nature of the TLA 
substrate, Boc-LLR-AMC, TLA which was sensitive to epoxomicin was regarded as 
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‘true’ proteasomal TLA (Table 2b). Data in Table 2b show that ‘true’ TLA was not 
reduced by low or high levels of either MPP+ or dopamine; indeed TLA appeared to 
be activated by 100 µM MPP+ and 500 µM dopamine.
Effect of MPP+ and dopamine on CLA, ATP and glutathione levels in SH-SY5Y 
cells.
The possible roles of ATP and glutathione in maintaining proteasomal activity in 
response to MPP+ and dopamine treatment was assessed, focusing on CLA since it is 
the most well characterized and was sensitive to MPP+/dopamine treatment.
Control SH-SY5Y cells typically contained 5.5 ± 1.2 nmols of ATP and 20.8 ± 3.7
pmols of glutathione per µg of protein. Figure 2 represents a time course of CLA, 
ATP and glutathione levels after treatment with 100 µM and 2 mM MPP+ in 
comparison to controls. MPP+ affects CLA, ATP and glutathione levels in a dose and 
time-dependent manner. The first significant change with 100 µM MPP+ was a 
reduction in glutathione levels (30 % at 48 h and 56 % at 72 h), followed by a small 
reduction (20 %) in ATP at 48/72 h. 100 µM MPP+ had no significant effect on CLA 
activity at 24 h and 48 h, however it was reduced by 30 % at 72 h. 
With 2 mM MPP+ the first significant change was again a reduction in glutathione, 
which occurred at 24 h (31 %) increasing to 67 % and 82 % after 48 h and 72 h. CLA 
was also reduced earlier with 2 mM MPP+ than with 100 µM MPP+, being 
significantly reduced by 46 % at 48 h and 78 % at 72 h. As for CLA, ATP levels were 
also reduced by the 48 h time-point (48 % reduction cf. controls, increasing to 69 %
after 72 h). It thus appears that a reduction in both glutathione and ATP are needed 
prior to a reduction in CLA.
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The effects of 100 µM dopamine on CLA were similar to MPP+ (30 % reduction at 72 
h); in this case, however, glutathione levels were significantly increased (176 % cf. 
controls) at 24 h and were not reduced (by 23 %) until 72 h. ATP levels were not 
affected by this concentration of dopamine at any of the time points tested (Fig. 3). 
With 500 µM dopamine, glutathione was again increased at 24 h (200 % in 
comparison to controls), but was reduced by 17 % and 77 % at 48 and 72 h 
respectively. ATP levels were non-detectable by 48 hours but CLA was not 
significantly reduced until 72 h. Thus it appears that ATP is less important for 
maintenance of CLA in the presence of dopamine in this system. 
Assessment of the level of reactive oxygen species (ROS) in SH-SY5Y cells
following toxin exposure.
To investigate the possible implication of increased ROS in MPP+ and dopamine 
toxicity in our model, 2,7-dichlorodihydrofluorescein diacetate (DCHDF), a dye 
which is used as an indicator of peroxynitrate formation, was used. Following 
enzymatic or base-catalysed cleavage of the diacetate group, DCFDH is readily 
oxidised to the highly fluorescent product dichlorofluorescein (DHF). The formation 
of DHF can be monitored by confocal laser microscopy.
Cells in 8-well chamber slides were treated with 2 mM MPP+, 100 µM dopamine or 2 
mM BSO for up to 72 h. Since higher concentrations of dopamine (i.e. 500 µM and 2 
mM) caused significant detachment from these chamber slides, a concentration of 100 
µM had to be used for these experiments. A large increase in the level of ROS was 
evident when cells were exposed to dopamine, in contrast to cells exposed to MPP+
where ROS production was low (Fig. 4). Treatment of cells with 2 mM BSO (which 
blocks glutathione synthesis; Fig. 6) also resulted in the formation of large amounts of 
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ROS. To investigate whether ROS formation could be blocked the effect of N-acetyl 
cysteine (NAC; at 1 mM), a precursor for glutathione, was included. Indeed, 
dopamine and MPP+ treated cells incubated in the presence of NAC showed a 
reduction in the level of ROS formed.
Effect of anti-oxidants on proteasomal activity following toxic insult
To establish whether the decrease in proteasomal activity caused by the toxins could 
be partly due to oxidative stress, the effect 1 mM NAC on proteasomal activity of SH-
SY5Y cells after 72 h exposure to toxic concentrations of MPP+ and dopamine was 
monitored.
Figure 5A shows that NAC alone had no effect on CLA but 2 mM MPP+ or dopamine 
drastically reduced CLA to 13.7 % and 0.5 % of controls, respectively. In the case of 
dopamine, the decrease in proteasomal activity by this highly toxic concentration (2 
mM) was significantly reversed by 1 mM NAC (activity increasing from 0.5 % to 
52.3 % of control). However, 1 mM NAC did not significantly protect CLA from 
MPP+ toxicity. Similar results were obtained with other anti-oxidants (including 
ascorbic acid, data not shown). Visualization of cell morphology of cells exposed to 
toxins alone and cells exposed to toxins in the presence or absence of NAC also 
suggested that NAC could partly reverse the effects of dopamine, but not MPP+ (Fig.
5B). Furthermore cells treated with dopamine and NAC were healthy and the 
autooxidation of dopamine, as evidenced by the colour of the growth medium, was 
prevented by NAC. These data indicate that the effects of dopamine (but not MPP+) 
on cellular proteasome activity are likely to be primarily due to oxidative damage. 
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Glutathione depletion results in a reduction in both CLA and ATP levels in SH-
SY5Y cells
To investigate whether glutathione depletion may be involved in reductions in CLA
following treatment with MPP+ and dopamine, glutathione levels were artificially 
depleted by 2 mM L-buthionine-[S,R]-sulfoximine (BSO), an inhibitor of - glutamyl 
cysteine synthase, an enzyme involved in the glutathione biosynthetic pathway.
As expected, 2 mM BSO virtually depleted glutathione levels as early as 24h (Fig. 6). 
ATP levels were also reduced by 20-30 % after 48 and 72 h and by 65 % after 96 h. 
Although CLA was reduced by around 30 % at 72 h, the reduction in CLA was only 
significant (> 50 %) after 96 h treatment with 2 mM BSO, suggesting that depletion 
of glutathione levels can eventually lead to proteasome impairment, possibly 
involving effects on ATP synthesis. 
Effect of glutathione depletion on CLA in MPP+- and dopamine-treated cells
As indicated earlier, glutathione depletion alone using BSO (2 mM) over 72 h had no 
significant effect on CLA (Fig. 6) whilst a 72 h exposure to 100 µM MPP+ or 
dopamine resulted in a reduction in CLA (Figs. 2 and 3). However, when BSO was 
added in the presence of MPP+ or dopamine , it caused a further significant reduction 
in CLA (Fig. 7). 
Direct effect of MPP+, MPTP and dopamine on CLA, TLA and PLA activities in 
purified 20S proteasome. 
The effects of MPP+ and dopamine on CLA in cell extracts was initially tested by 
addition of these toxins directly to a fluorogenic peptide assay containing 25-30 µg 
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cell extract. Whilst 100 µ MPP+ and dopamine had no effect, both 2 mM MPP+ and 
2 mM dopamine significantly reduced CLA by 13 % of controls (data not shown). 
The direct effects of the toxins on the three activities of purified human 20S were also 
tested, in order to check if (a) the different activities were sensitive to these chemicals 
and (b) whether the three activities were affected to the same extent. Both dopamine 
and MPP+ reduced all three proteasomal activities but the sensitivity to low toxin 
concentrations was generally in the order of CLA>PLA >TLA (Table 3). All three 
activities appeared more sensitive to dopamine treatment than to MPP+ (this is 
particularly evident with 500 µM MPP+/dopamine, Table 3). In addition the effect of 
MPTP, which gives rise to MPP+ via oxidative deamination, was also checked. 
Surprisingly, MPTP also reduced CLA and PLA (PLA being the most sensitive) but 
did not affect TLA.
Effect of ascorbic acid (vitamin C) and N-acetyl-cysteine (NAC) on neurotoxin–
mediated reductions in purified human 20S proteasome activity.
Both Vitamin C and NAC protected CLA of the purified 20S proteasome against 2
mM MPP+, MPTP and dopamine (Table 3) to a similar extent. Less vitamin C was 
needed to reverse the effects of MPP+ and MPTP than dopamine, indicative of the 
stronger oxidative nature of dopamine (results not shown). 
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Discussion 
This paper reports a study of the effects of two compounds of relevance to PD on the 
human proteasome; MPP+ since it is known to reproduce some of the biochemical 
deficits of PD including inhibition of complex I (Forno 1996; Przedborski and 
Jackson-Lewis 1998), and dopamine because dopaminergic neurons are selectively 
lost in PD and dopamine is implicated in the disease process (Asanuma et al. 2003; 
Smythies 1999). We have addressed the relative roles of ATP and ROS in the
determination of proteasome activity using human dopaminergic neuroblastoma cells, 
since previous work used rat cells. In particular we have concentrated on glutathione 
levels and have assessed all three proteolytic activities of the proteasome. By also 
studying the direct effects of these toxins on purified 20S activities we have been able 
to distinguish between the primary and secondary effects of the toxins on the 
proteasome. 
Our results show that both complex I inhibition by MPP+ and the presence of 
dopamine lead to a reduction in CLA and PLA (but not TLA) in our cells. We have 
also shown, for the first time that MPP+ and dopamine added directly to purified 20S 
proteasome samples cause a reduction in proteasomal activity; with dopamine being 
more damaging and 20S-CLA most sensitive, followed by 20S-PLA and 20S-TLA. 
All three activities have previously been assessed in a limited number of human post-
mortem PD samples (McNaught et al. 2003; McNaught and Jenner 2001), in rodent 
models treated chronically with MPTP (Fornai et al., 2005) or rotenone (Betarbet et 
al. 2006) and in rodent cell lines treated with complex 1 inhibitors (rotenone and 
MPP+; Hoglinger et al. 2003) and 6-hydroxydopamine (Elkon et al. 2004). In these 
reports no attempt has been made to confirm the activities reported are truly 
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proteasomal and no differences in sensitivity between the three activities were 
highlighted. However, close inspection of the data would indicate that differences did 
exist in some instances (McNaught and Jenner 2001; Elkon et al. 2004; Fornai et al., 
2005). A difference in sensitivities of the three activities is of great interest since the 
three active sites contribute differently and independently to protein breakdown 
(inhibition of multiple sites is required to markedly decrease proteolysis) and their 
relative importance varies with the substrate (Kisselev et al., 2006).
The effects of dopamine and MPP+ on purified 20S-CLA in vitro were reversed by 
ascorbic acid. Since ascorbic acid may form direct complexes with test compounds, 
independent of its antioxidant properties (Zou et al., 2006), we confirmed that the 
effects of dopamine and MPP+ were via an oxidative mechanism by showing that 
NAC could also attenuate the loss in 20S activity. Indeed dopamine is well known to 
be a strong oxidant and MPP+ has previously been reported to cause direct oxidative 
damage to proteins (Joffe et al. 1998; Cassarino et al. 1999; Cappelletti et al. 2005). 
We find that MPTP (which can oxidise at room temperature in solution; Przedborski 
et al., 2001), also causes oxidative damage to 20S-CLA and 20S-PLA but has no 
significant effect on 20S-TLA. This supports the lower sensitivity of 20S-TLA in 
human cells. The nature of the inhibition of purified 20S proteasome by MPP+, MPTP 
and dopamine appears to be non-competitive (Km unaffected, Vmax reduced; 
Supplementary Figure 1). The fact that the three PD mimetics used in this study could 
directly affect 20S activity would suggest that chemicals with this type of structure 
may have direct deleterious effects on the UPS in vivo, acting as non-competitive 
inhibitors, if their concentrations are sufficiently high. In support of this we found that 
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2 mM MPP+ and 2 mM dopamine consistently reduced CLA, albeit by only 13%, 
when added to control cell extracts.
The fact that TLA activity was not reduced in cells and least affected in the 20S 
samples would suggest that the subunits involved with the catalytic aspects of TLA 
(namely 2, 6) or TLA regulation (-subunits.) are less sensitive to oxidative stress, 
at least in human proteasomes exposed to damaging compounds/environments for 
relatively short time periods. Interestingly, similar direct effects of MPP+, MPTP and 
dopamine were observed on the activity of pure trypsin enzyme; however, 20S-TLA 
was more sensitive than trypsin to dopamine (results not shown). This may indicate 
that some of the oxidative damage could be affecting the non-catalytic subunits which 
can moderate 20S-TLA.
When complex 1 in SH-SY5Y cells is inhibited by MPP+ we find that both ATP and 
glutathione are depleted, but that ATP levels are likely to be the most important in 
determining whether or not CLA is reduced since removal of ROS via NAC does not 
protect against the effect. This is similar to the situation in rat primary mesencephalic 
cultures where ATP appeared to be reduced to a threshold level by MPP+ and 
rotenone (20% of control value following a 6hr exposure) prior to generalized cell 
death linked with a 30-60 % reduction in UPS activity. Increasing ATP levels to 
approximately 40% of controls, by glucose supplementation, reversed the effect on 
proteasomal activities (Gluck et al. 2002; Hoglinger et al. 2003). However, in the 
present study ATP levels were reduced to only 80 % of controls by MPP+ treatment 
before significant reductions in CLA occurred. This may suggest that human cells are 
more sensitive than rat cells to MPP+ toxicity. Whilst proteasome impairment can be 
Page 22 of 47Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
23
mediated via ATP depletion it can also be independently influenced by ROS. Indeed, 
we find that glutathione depletion with BSO exacerbates the effect of MPP+ on CLA. 
Betarbet et al (2006) showed that chronic exposure of human SK-N-MC 
neuroblastoma cells to rotenone reduced the UPS, an effect dependant on complex 1 
inhibition, but in this case without ATP depletion. The effect was attenuated by -
tocopherol, indicating the involvement of oxidative stress with this complex 1 
inhibitor. So it would appear that different complex 1 inhibitors have different effects.
Following treatment of SH-SY5Y cells with high levels of dopamine ATP depletion 
also occurred, presumably via complex 1 inhibition as previously shown in 
mitochondrial samples (Morikawa et al. 1996; Ben-Shachar et al. 2004) and in intact 
cells (Morikawa et al. 1996; Blum et al. 2001; Gimenez-Xavier et al. 2006). Indeed,
in our experiments ATP levels were drastically reduced following a 24 h exposure to 
500 µM dopamine. However, CLA was not affected until later time points. ATP 
levels were unaffected by 100 µM dopamine during a 72 h time-course, but CLA was 
significantly reduced. As expected dopamine was seen to produce vast amounts of 
ROS which could directly damage the proteasome, since the effects of dopamine on 
CLA were reversed by the anti-oxidant, NAC.  The fact that dopamine treatment 
resulted in early increases in glutathione levels, as previously reported (Dringen 2000; 
Haque et al. 2003), supports the notion that the cells are responding to oxidative 
stress. Indeed dopamine did not lead to decrease in proteasomal activity until 
glutathione levels had been reduced. In addition, when dopamine was added together 
with BSO, CLA activity was further affected. We also found that dopamine, added at 
very high concentrations, could reduce 20S activity of cell extracts. Thus in the 
presence of dopamine, ATP levels are less important than ROS levels in the 
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maintenance of proteasomal activity, as is the case for cell viability in general (Blum
et al. 2001; Morikawa et al. 1996).
As argued recently (Morikawa et al. 1996; Blum et al. 2001; Gimenez-Xavier et al.
2006) although dopamine concentrations of 100-500 µM, as used in this work, would 
be considered as being above normal physiological values, since extracelluar 
concentrations are reported to be of the order on nM in the substantia nigra and 
striatum, the intracellular striatum concentration is estimated to be around 70 µM, 
whilst the concentration in neuronal endings can be in the mM range. Thus it would 
seem likely that the extracellular dopamine concentrations used in the present study 
would lead to intracellular concentrations that are found in vivo in dopaminergic 
neurons with disrupted vesicles or vesicles not storing dopamine efficiently.
It has been reported that the ATP and ubiquitin dependent 26S is four times more 
vulnerable to oxidative stress than 20S (Reinheckel et al. 1998). This could be related 
to possible oxidative effects on the various regulatory subunits of the 26S proteasome
(McNaught et al. 2003; Ishii et al. 2005). However, oxidative damage is not solely 
confined to the regulatory subunits since the -subunits of the 20S are also reported to 
be targets in SH-SY5Y cells (Shamoto-Nagai et al. 2003). Whether or not the toxins 
lead to selective loss or damage to specific proteasome subunits is currently being 
studied in our system. It is entirely possible that some of the effects detected via 
measurement of 20S activity in our cellular homogenates occur via damage to the 
regulatory subunits, given that our extraction system contained ATP and would 
conserve at least some 26S particles (Coux et al. 1996). More importantly, a reduction 
in intracellular ATP levels (discussed above) could result in the dissociation of 26S 
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proteasomes into the less active 20S proteasome (Bernaroudj et al. 2003; Kisselev and 
Goldberg, 2005). This could therefore contribute, in part, to the reduction in the 
measured activity.
Thus our work add further support to the suggestion that complex 1 inhibition/defects, 
whether due to the effects of toxins or due to genetic predisposition, leads to selective 
problems in dopamine containing neurons since both oxidative stress and ATP 
depletion will contribute independently to loss of proteasomal function. It is likely 
that complex 1 inhibition in non-dopamine containing cells would be less damaging, 
and in this case ATP depletion rather than ROS would be the important determinant 
of 20S activity. It should also be noted that, since both MPP+ and dopamine cause 
oxidative damage to purified 20S, they could have a significant direct effect on 
cellular proteasomal activity, provided their intra-cellular concentrations are high.
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% Inhibition
SAMPLE Inhibitor Concentration (µM) CLA TLA PLA
Lactacystin 10 95** 72* 0
Epoxomicin 10 100** 98** 80**20S Proteasome
MDL 28170 10 25** 58** 0
Lactacystin 10 94** 0 0
Epoxomicin 10 99** 25* 87*SH-SY5Y cell extracts
MDL 28170 10 0 67** 0
% Inhibition
SAMPLE Inhibitor Concentration (µM) Calpain Activity
Lactacystin 10 39**
Ep xomicin 10 0Calpain
MDL 28170 10 98**
Table 1. Inhibitory effects of lactacystin, epoxomicin and MDL 28170 on purified 
20S proteasome, calpain and proteasomal activity of SH-SY5Y cell extracts.
Commercial sources of 20S proteasome (0.05 µg) and calpain (3.6 µg) and SH-SY5Y 
cell extracts (25 µg) were incubated in the presence of lactacystin, epoxomicin or 
MDL 28170, prior to the addition of substrate and the measurement of activity. 
Results were calculated as FU/s/µg protein and expressed as % inhibition in 
comparison to control samples.  When no significant inhibition was seen values were 
assigned “0 % Inhibition”. Data presented are from a representative experiment where 
n=3. Statistical analysis was carried out using a two-tailed Student’s t-test. Statistical 
significance was accepted when *= p<0.05 or ** = p< 0.01 cf. control. 
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(a)
Substrate Treatment Conc (mM)
Proteasomal Activity
(102FU/s/µg) 
Activity
(%)
Epoxomicin
(% Inhibition) 
CLA Control
MPP+
Dopamine
0
0.1
2
0.1
0.5
2.89 ± 0.41
2.38 ± 0.24
0.58 ± 0.34
3.02 ± 0.72
1.60 ± 0.60
100.0
82.5
20.2*
104.5
55.6*
98.9**
100.0**
100.0**
100.0**
100.0**
TLA Control
MPP+
Dopamine
0
0.1
2
0.1
0.5
24.5 ± 0.77
39.8 ± 1.16
21.2 ± 1.55
27.4 ± 1.18
28.3 ± 1.68
100.0
162.7**
86.9
112.2
115.8
25.4*
31.3*
27.4*
22.9*
32.2**
PLA Control
MPP+
Dopamine
0
0.1
2
0.1
0.5
1.65 ± 0.08
1.62 ± 0.09
0.17 ± 0.18
1.65 ± 0.17
0.79 ± 0.09
100.0
98.6
10.2**
100.3
48.2**
87.2*
89.3*
63.4*
91.1*
100.0**
(b)
Substrate Treatment Conc 
(mM)
Estimated ‘true’ TLA
(%)
TLA Control
MPP+
Dopamine
0
0.1
2
0.1
0.5
100.0 ±  8.4
194.0 ± 3.4**
93.5 ± 23.9
99.3 ±4.3
142.5 ± 25.9*
Table 2. Effect of MPP+ and dopamine on proteasomal activities from SH-SY5Y cells after 72h 
exposure. (a) Cells were treated with MPP+ and dopamine for 72 h prior to extraction in 
homogenisation buffer. Proteasome activity (CLA, TLA and PLA) was measured and results presented 
as FU/s ± SEM and then converted to mean % activity (cf. control samples). To confirm the activity 
measured was proteasomal, sample activity was measured in the presence or absence of epoxomicin 
(10 µM) and the % inhibition calculated. When no significant inhibition was seen values were assigned 
“0 % Inhibition”. The data presented are from a representative experiment with assays replicated in 
triplicate. Statistical analysis was carried out using a Student’s t-test comparing toxin treated samples 
to their corresponding control. Statistical significance was accepted when *= p<0.05 or ** = p< 0.01. 
(b) Since the measured TLA contains only a fraction of actual proteasomal TLA, ‘true’ TLA activities 
were estimated using the appropriate correction factor based on epoxomicin inhibition. Statistical 
analysis was carried out using a Student’s t-Test comparing toxin treated samples to TLA control.
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Proteasomal Activity (% cf. control)
CLA TLA PLATreatment
Conc
(mM)
+ AA + NAC
MPP+ 0.01
0.1
0.5
2.0
85.4
71.4**
43.3**
46.1** 70.0## 88.5##
92.9
83.3
69.9**
57.6**
88.0
89.9
31.6**
0.3**
MPTP 0.01
0.1
0.5
2.0
91.3
93.4
66.1**
27.6** 86.4## 83.5##
97.9
97.0
99.6
89.4
70.1**
75.5**
11.8**
0.0**
Dopamine 0.01
0.1
0.5
2.0
29.0**
32.6**
12.7**
0.3** 70.2## 40.4##
92.2
79.4**
0.0**
0.0**
65.2**
72.5**
0.0**
0.0**
Table 3. Effects of MPTP, MPP+ and dopamine on purified human 20S proteasome
and the protective effect of ascorbic acid and N-acetyl-cysteine. 
Purified 20S proteasome (0.05 µg) was incubated in the presence or absence of MPP+, 
MPTP or dopamine for 10 min, prior to measuring CLA, TLA and PLA for 1 hour. The 
effect of ascorbic acid (+AA; 1 mM) or N-acetyl-cysteine (+NAC; 1 mM) on CLA in 
the presence of 2 mM MPP+, MPTP, or dopamine was also measured. All results are 
presented as mean % activity in comparison to corresponding controls. Statistical 
analysis was carried out using the Student’s t-test comparing toxin treated samples with 
corresponding controls (**= p<0.01; n=5) and comparing toxin treated CLA activity 
with either ascorbic acid or NAC treated CLA activity (## = p<0.01, n=4). N.B. Ascorbic 
acid (1 mM) and NAC (1 mM) alone had no significant effect on CLA activity.
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Fig. 1 Assessment of cell viability in SH-SY5Y cells following MPP+ or dopamine 
exposure. Cells were seeded in 96 well plates at a density of 10,000 cells/well. After 
24 h medium was exchanged for fresh growth medium supplemented with/without 
MPP+ (100 µM, 2 mM) or dopamine (100 µM, 500 µM) and incubated for a further 
24, 48 or 72 h, prior to viability assessment using the MTT reduction assay. Data 
presented are mean cell viability + SEM from three independent experiments. 
Statistical analysis was carried out using the Student’s t test comparing toxin treated 
cells with corresponding time point control, where *= p<0.05.
Fig. 2 Effect of MPP+ on CLA, ATP and glutathione levels in SH-SY5Y cells. Cells 
were exposed to 100 µM or 2 mM MPP+ for 24, 48 and 72 h prior to assessment of 
CLA, ATP or glutathione content. Values were calculated as activity/µg protein and 
then expressed as % activity (cf. control) ± SEM, where n>3. Statistical analysis was 
carried out using the Student’s t test comparing cells exposed to MPP+ against time 
point controls, where *= p<0.05.
Fig. 3 Effect of dopamine on CLA, ATP and glutathione levels in SH-SY5Y cells.
Cells were exposed to 100 µM or 500 µM dopamine for 24, 48 and 72 h prior to 
assessment of CLA, ATP or glutathione content. Values were calculated as 
activity/µg protein and then expressed as % activity (cf. control) ± SEM, where n>3. 
Statistical analysis was carried out using the Student’s t test comparing cells exposed 
to dopamine against time point controls, where *= p<0.05.
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Fig. 4 Determination of the level ROS in SH-SY5Y cells following toxin insult. SH-
SY5Y cells were plated out in chamber slides and treated with toxins for 72 h: control 
(a); 2 mM BSO (b); 2 mM MPP+ (c); 100 µM dopamine (d). The addition of NAC (1 
mM) to the incubation media was also monitored in cells exposed to 2 mM MPP+ (e) 
or 100 µM dopamine (f) for 72 h. Levels of ROS were determined in the presence of 
100 µM DCHDF, pre-loaded for 30 minutes prior to analysis by confocal laser 
scanning microscopy. Scale bar represents 100 µm. 
 
Fig. 5 Effect of NAC on CLA and cell morphology after 72 h exposure to MPP+ or 
dopamine. SH-SY5Y cells were exposed to MPP+ (2 mM) or dopamine (2 mM) in the 
presence or absence of 1 mM NAC for 72 h. CLA was monitored using the 
fluorogenic peptide assay and results were calculated as FU/s/µg and then expressed 
as Mean % Activity + SEM (cf. control samples) – panel (a). The data shown are
from a representative experiment with assays replicated three times. Statistical 
analysis was carried out using a Student’s t-test. Cells exposed to both toxin and 
antioxidant were compared to cells exposed to toxin alone. Statistical significance was 
accepted when * = p< 0.05 cf. control or # =p< 0.05 cf. toxin control. Panel (b)
represents photographs of cells exposed to either MPP+ or dopamine in the presence 
or absence of 1 mM NAC following 72 h exposure. Images were acquired with a 
Nikon eclipse TS100 inverted microscope. Scale bar = 50 µm.
Fig. 6 Effect of BSO on CLA, ATP and glutathione levels in SH-SY5Y cells. Cells 
were exposed to 2 mM BSO for 24, 48, 72 and 96 h prior to assessment of CLA, ATP 
or glutathione content. Values were calculated as Activity/µg protein and then 
expressed as % Activity (cf. control) ± SEM, where n=3. Statistical analysis was 
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carried out using the Student’s t test comparing cells exposed to BSO against time 
point controls, where * = p< 0.05.
Fig. 7 Effect of glutathione depletion on CLA following a 72h exposure to 100 µM 
MPP+ or dopamine. SH-SY5Y cells were exposed to MPP+ (100 µM) or dopamine 
(100 µM) in the presence or absence of 2 mM BSO for 72h, prior to analysis of CLA. 
Results were calculated as FU/s/µg and then expressed as mean % Activity (cf. 
control) + SEM. Statistical analysis was carried out using a Student’s t-test comparing 
samples treated with toxin (MPP+, n=4 or dopamine, n=5) to control samples or 
comparing samples treated with toxin + BSO to samples treated with toxin alone. 
Statistical significance was accepted when * = p< 0.05 cf. control or # = p<0.05 cf. 
toxin control.
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(a) Control (b) 2 mM BSO
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15.47 ± 3.91*36.65 ± 7.91100 µM Dopamine
18.39 ± 2.54*26.63 ± 4.51500 µM MPTP
21.66 ± 4.28*44.06 ± 9.67500 µM MPP+
29.49 ± 3.4041.22 ± 7.60Control
Vmax (pmoles/min/µg ± SEM)km (µM ± SEM)Treatment
Supplementary Figure 1. Kinetic analysis of the inhibitory effects of MPP+, MPTP and dopamine 
on the chymotrypsin-like activity of the 20S proteasome. Purified 20S proteasome (0.05 µg) was 
incubated in the absence (control, ) or presence of 500 µM MPP+ (), 500 µM MPTP () or 100 
µM dopamine () for 10 min, prior to measuring CLA for up to 2 hours. Shown are:
(a) typical Michaelis-Menten kinetics; data are mean values for triplicate assays, 
(b) Linewever-Burke plot for data in (a) 
(c) Vmax and Km values. Data are the mean values of four experiments performed in triplicate and 
analysed by the Student’s t test comparing toxin treated values for Vmax and Km with corresponding 
control values.
(c)
(a)
(b)
[CLA Substrate, µM] 
1/[CLA Substrate, µM] 
1/
R
at
e
0.10
0.20
0.30
-0.05 0 0.05 0.1 0.15 0.2
0
5
10
15
20
25
30
0 20 40 60 80 100
R
at
e 
(p
m
o
l/m
in
/u
g)
Page 47 of 47 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
